POPULARITY
Categories
369 episodes with CMC
278 episodes with CMC
180 episodes with CMC
68 episodes with CMC
115 episodes with CMC
57 episodes with CMC
39 episodes with CMC
88 episodes with CMC
33 episodes with CMC
47 episodes with CMC
109 episodes with CMC
34 episodes with CMC
36 episodes with CMC
29 episodes with CMC
22 episodes with CMC
41 episodes with CMC
24 episodes with CMC
81 episodes with CMC
28 episodes with CMC
10 episodes with CMC
83 episodes with CMC
20 episodes with CMC
16 episodes with CMC
20 episodes with CMC
28 episodes with CMC
20 episodes with CMC
54 episodes with CMC
8 episodes with CMC
14 episodes with CMC
18 episodes with CMC
14 episodes with CMC
18 episodes with CMC
14 episodes with CMC
18 episodes with CMC
9 episodes with CMC
8 episodes with CMC
9 episodes with CMC
8 episodes with CMC
21 episodes with CMC
8 episodes with CMC
15 episodes with CMC
10 episodes with CMC
10 episodes with CMC
4 episodes with CMC
8 episodes with CMC
7 episodes with CMC
12 episodes with CMC
7 episodes with CMC
10 episodes with CMC
9 episodes with CMC
8 episodes with CMC
18 episodes with CMC
7 episodes with CMC
36 episodes with CMC
4 episodes with CMC
8 episodes with CMC
10 episodes with CMC
7 episodes with CMC
15 episodes with CMC
7 episodes with CMC
5 episodes with CMC
6 episodes with CMC
7 episodes with CMC
9 episodes with CMC
6 episodes with CMC
7 episodes with CMC
5 episodes with CMC
4 episodes with CMC
7 episodes with CMC
7 episodes with CMC
17 episodes with CMC
5 episodes with CMC
7 episodes with CMC
7 episodes with CMC
4 episodes with CMC
5 episodes with CMC
7 episodes with CMC
5 episodes with CMC
4 episodes with CMC
9 episodes with CMC
3 episodes with CMC
4 episodes with CMC
6 episodes with CMC
6 episodes with CMC
5 episodes with CMC
7 episodes with CMC
3 episodes with CMC
8 episodes with CMC
9 episodes with CMC
4 episodes with CMC
5 episodes with CMC
7 episodes with CMC
5 episodes with CMC
16 episodes with CMC
4 episodes with CMC
5 episodes with CMC
8 episodes with CMC
3 episodes with CMC
5 episodes with CMC
6 episodes with CMC
5 episodes with CMC
4 episodes with CMC
4 episodes with CMC
6 episodes with CMC
11 episodes with CMC
9 episodes with CMC
9 episodes with CMC
5 episodes with CMC
4 episodes with CMC
5 episodes with CMC
5 episodes with CMC
5 episodes with CMC
3 episodes with CMC
8 episodes with CMC
11 episodes with CMC
4 episodes with CMC
4 episodes with CMC
6 episodes with CMC
12 episodes with CMC
2 episodes with CMC
10 episodes with CMC
4 episodes with CMC
4 episodes with CMC
4 episodes with CMC
3 episodes with CMC
3 episodes with CMC
3 episodes with CMC
5 episodes with CMC
3 episodes with CMC
4 episodes with CMC
14 episodes with CMC
4 episodes with CMC
7 episodes with CMC
71 episodes with CMC
4 episodes with CMC
5 episodes with CMC
3 episodes with CMC
4 episodes with CMC
2 episodes with CMC
4 episodes with CMC
3 episodes with CMC
3 episodes with CMC
5 episodes with CMC
5 episodes with CMC
4 episodes with CMC
67 episodes with CMC
4 episodes with CMC
4 episodes with CMC
4 episodes with CMC
3 episodes with CMC
2 episodes with CMC
3 episodes with CMC
2 episodes with CMC
2 episodes with CMC
2 episodes with CMC
7 episodes with CMC
2 episodes with CMC
3 episodes with CMC
5 episodes with CMC
3 episodes with CMC
3 episodes with CMC
3 episodes with CMC
Today, we examine a year that looked chaotic but felt familiar to trend followers. Gold surged, equities rotated globally, and non-US markets quietly gained momentum. Yet beneath strong returns lies a deeper debate about model design, short versus long horizon signals, and whether innovation in liquid alternatives serves investors or sales desks. From AI disruption to product engineering and allocator behavior, this episode explores where systematic strategies truly create value and where structural incentives distort outcomes. In a changing macro regime, clarity of purpose may matter more than ever.-----50 YEARS OF TREND FOLLOWING BOOK AND BEHIND-THE-SCENES VIDEO FOR ACCREDITED INVESTORS - CLICK HERE-----Follow Niels on Twitter, LinkedIn, YouTube or via the TTU website.IT's TRUE ? – most CIO's read 50+ books each year – get your FREE copy of the Ultimate Guide to the Best Investment Books ever written here.And you can get a free copy of my latest book “Ten Reasons to Add Trend Following to Your Portfolio” here.Learn more about the Trend Barometer here.Send your questions to info@toptradersunplugged.comAnd please share this episode with a like-minded friend and leave an honest Rating & Review on iTunes or Spotify so more people can discover the podcast.Follow Andrew on Twitter.Episode TimeStamps: 00:00 - Introducing the Systematic Investor series01:17 - AI disruption and systematic investing06:52 - The shifting perception of US risk09:21 - Winter Olympics and market metaphors12:59 - Hedge funds versus private equity19:23 - 2025 review and the importance of risk allocation22:17 - Why CTAs did not fully capture gold29:48 - Short term versus long term trend models35:27 - Letting risk run versus investor palatability44:43 - The problem with liquid alternatives51:21 - Product design versus fiduciary duty59:06 - QIS, innovation and investor sophistication01:04:41 - Model risk and the myth of risk premia01:10:51 - Hopes for a trending year aheadCopyright © 2025 – CMC
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 Years on Feedspot. Sonal's 17th Season starts up and Episode 2 features a Newsworthy update on the OIG Work Plan for January 2026.Sonal's Trusty Tip and compliance recommendations focus on the new industry segment-specific compliance guidance document issued by the OIG for Medicare Advantage parties.Spark inspires us all to reflect on beauty, abundance, and innovation based on the inspirational words of Elisabeth Kübler Ross.Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
Recorded: February 09, 2026 Welcome to another episode of Bussin' With The Boys featuring special guest, 49ers star running back and NFL comeback player of the year, Christian McCaffrey. Will Compton & Taylor Lewan sit down with christian McCaffrey fresh off his Comeback Player of the Year season and carrying the load for a beat-up 49ers roster, CMC gets real about the responsibility of being the guy, the mental side of the grind, and how this season tested him. The conversation also touches on Mac Jones’ strong year, George Kittle battling injuries, and some legendary behind the scenes football talk including stories about Julius Peppers’ freak athleticism and why Luke Kuechly was the gold standard on the practice field in Carolina, when CMC was at the Panthers. Outside the game, CMC talks through how he decompresses, what his daily training routine actually looks like in season, stepping into fatherhood, and how growing up playing multiple sports helped build his skill set. Plus, there’s a classic Super Bowl week moment thrown in that perfectly sums up the chaos of the week. If you’re about top-tier RB play, behind-the-scenes Super Bowl stories, and real locker room football conversations, this one’s for you. 0:00 Intro4:18 KNF Clean Take6:03 Super Bowl Recap8:12 Will Finally Got His House Setup11:01 Taylor Hit Vegas17:46 How Would You Change Super Bowl Week26:05 Guest Rolodex Coming Up31:33 Gooner Of The Month34:40 CHRISTIAN MCCAFFREY INTERVIEW STARTS34:48 CMC Came Through For The Boys36:08 Winning Comeback Player Of The Year40:14 Did He Think About His Mortality?45:01 Him Being “The Guy” This Season & The 49ers Injuries50:24 Dynamic With Mac Jones Balling Out51:25 George Kittle Getting Hurt56:16 What's The Deal Will With The Electrical Substation?1:10:20 How Does CMC Relieve Stress?1:13:36 Training Day In The Life Of CMC1:17:30 Julius Peppers Is A Freak1:19:29 Luke Kuechly Was More Athletic Than People Think1:21:45 Becoming A Father1:28:45 Growing Up Playing Different Sports1:37:01 Bud Light QuestionSee omnystudio.com/listener for privacy information.
When your biosimilar analytical data shows 1.4% high mannose against a 6% reference product specification, you face limited options: process temperature shifts that compromise titer, kifunensine supplementation that requires extensive regulatory justification, or 12-18 months to reclone and revalidate. Media supplementation offers an alternative pathway—tuning glycan profiles through formulation adjustments rather than cell line or process re-engineering.In this episode, David Brühlmann presents the experimental development of a media supplementation strategy that achieved 2.8-fold increases in high mannose glycans across multiple CHO cell lines. Drawing from research published in the Journal of Biotechnology (2017, 252:32-42), the discussion covers the mechanism of raffinose-mediated glycan processing arrest, the experimental variables that initially obscured the effect, and the process development considerations for implementing media-based glycan tuning.The episode examines N-glycan biosynthesis in CHO cells, regulatory comparability requirements for biosimilar glycosylation profiles, and the experimental framework for evaluating media supplementation as a glycan control strategy.Highlights from the episode:The unexpected link between dietary raffinose and reduced athletic performance, and its connection to bioprocessing (01:11)A clear primer on the importance of glycosylation for biosimilar drugs and regulatory approval (02:43)Common challenges when glycan profiles don't match reference products, and why high mannose glycans matter (04:19)A review of industry strategies (temperature shifts, enzyme inhibitors, cell line reengineering) and their pitfalls (05:33)Mechanistic insights into how raffinose alters glycan processing in CHO cells (07:05)Key experimental findings on raffinose concentration, osmolality control, and practical lab troubleshooting (09:48)Application stories and regulatory considerations for implementing raffinose-based media adjustments (13:47)Closing thoughts on process optimization, regulatory impact, and what to expect in Part 2 (15:11)Strategic insight:Implementing raffinose as a media supplement is straightforward, regulatory-friendly, and cost-effective. It does not involve genetic engineering or enzyme inhibitors and is easily sourced as a GMP-grade material. For programs approaching submission with glycan comparability gaps, media-based tuning offers a process optimization pathway that maintains existing cell lines and manufacturing platforms while addressing critical quality attribute specifications.Listen to this episode of the Smart Biotech Scientist Podcast to learn David's best strategies for rapid, regulatory-friendly glycosylation control.If you want to transform your glycoengineering workflow, keep an eye (and ear) out for the next episode of the Smart Biotech Scientist Podcast. Your path to regulatory success might be as simple as a pinch of raffinose.Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Oppermachtig, president en partijleider voor het leven - de eerste sinds Mao. Xi Jinping wist zelfs Donald Trump te imponeren, ‘straight from Central Casting in Hollywood’. Dramatische gebeurtenissen in Beijing - zuivering van de militaire top, aanklachten wegens corruptie en atoomspionage, geruchten over een couppoging - duiden op grote troebelen en een onverwacht machtsvacuüm. Wat weten we, wat betekent dit en welke consequenties heeft dit voor China, voor Xi’s positie en de geopolitieke verhoudingen? *** Deze aflevering is mede mogelijk gemaakt met donaties van luisteraars die we hiervoor hartelijk danken. Word ook vriend van de show! Deze aflevering bevat een advertentie van Oogwereld Heb je belangstelling om in onze podcast te adverteren of ons te sponsoren? Zend ons een mailtje en wij zoeken contact. *** Jaap Jansen en PG Kroeger pluizen de berichten uit. Officiële verklaringen en commentaren in Beijing, maar ook de tsunami aan geruchten over de ongekende ingreep in de Centrale Militaire Commissie. Naast voorzitter Xi Jinping is nog maar één lid in functie. Vicevoorzitter generaal Zhang Youxia en chefstaf generaal Liu Zhenli zijn opgepakt. Ze worden beschuldigd van insubordinatie en 'verraad aan het vertrouwen van de Communistische Partij en haar Centraal Comité'. Vervolgens zijn bijna al hun collega's uit hun functie verwijderd en is in heel China in de topstructuur van de militaire districten en krijgsmachtonderdelen een massale zuivering en ontslaggolf gaande. Die formele beschuldiging wijst erop, dat hier geen sprake is van een verschil van inzicht over militaire kwesties alleen. De ingreep van Xi gaat veel dieper. Dit raakt aan de essentie van het vertrouwen tussen de partij, de politieke leiding en de leiding van het Volksbevrijdingsleger als geheel. En juist die balans van de twee machtscentra van de staat is cruciaal voor de ongebreidelde macht van Xi en die van zijn voorgangers als opperste leider en roerganger. Het conflict gaat dan ook over de continuïteit en fundamenten van die politieke macht, zoals in elke dictatoriale staat. Dit evenwicht is door het onthoofden van de CMC nu in één klap verwoest. De vraag naar die continuïteit van de macht is een vraag naar de betekenis en effecten van het feit dat Xi Jinping leider voor het leven is geworden. Dat roept hoe dan ook de vraag op: en wat dan? De militaire top wil zekerheid over wie hun opperbevelhebber zal zijn, terwijl van een breed gedragen regeling voor de opvolging - zoals Deng Xiaoping die ooit doorvoerde - geen sprake meer is. Wie daar hoe en wanneer over zal gaan is onhelder gehouden. In 2027 zal het volgende partijcongres daar wellicht over beslissen en ook in het Centraal Comité, in de machtige regio's was al enig rumoer merkbaar. De legertop was blijkbaar betrokken bij die onderhuidse signalen en eerdere zuiveringen indiceerden al spanningen en twijfels aan de koers van Xi. Bovendien was sprake van scherp toegenomen spanning over de voorziene aanpak van Taiwan. Het jaar 2027 staat daarin centraal. Dan wil Xi klaar zijn voor een definitieve aanpak van het weerspannige eiland en de hereniging tot één China realiseren. Daar komt nog iets bij dat van grote symbolische betekenis is. Dit najaar herdenkt China de dood van Mao Zedong in1976 en volgend jaar viert het 'honderd jaar Volksbevrijdingsleger'. Dat generaal Zhang insuborinatie pleegde, duidt erop dat hij de koers van Xi ten aanzien van Taiwan wel erg riskant vond en de voorbereidingen voor de invasie niet zonder meer wilde implementeren. Dat zou ertoe leiden dat Xi die grote regime-jubilea zou moeten laten passeren zonder het verwachte succes bij de nationale hereniging. Hij zou dan de al vele jaren bestaande strategie dat China in 2035 op gelijke voet met Amerika moet staan als enige wapenfeit over houden. Zijn gezag als partijleider komt zo in het geding. De vraagt rijst dan of de 74-jarige Xi niet door iemand uit een jongere generatie vervangen moet worden. Zie hier de verbinding tussen de strategische, geopolitieke dilemma's en de onopgeloste opvolgingsvraag. Ook de zeer sombere, soms dystopische speech van Xi bij het recente '75 Jaar Rood China' feest wordt hierdoor ineens veel beter te begrijpen. Heeft in China een dergelijk drama zich al eerder voltrokken? Al tijdens de jonge democratische republiek in de jaren twintig van de vorige eeuw was 'warlordism' een groot probleem. De zwakke democratische instituties werden permanent ondermijnd door regionale militaire bazen die met elkaar burgeroorlogen begonnen en soms ook met Japan samenwerkten tegen de republiek. Mao kon hen met zijn Volksbevrijdingsleger tegen elkaar, Japan en de Kuomintang uitspelen en won zo de overhand. In crisisfasen van Mao's regime - zoals de Grote Sprong Voorwaarts en de Culturele Revolutie - doken onmiddellijk zulke regionale conflicten en warlords weer op. Het leger drukte dit telkens hardhandig te kop in, met een sleutelrol voor maarschalk Ye Jianying. Die was ook cruciaal in de meest opmerkelijke couppoging. In 1971 deed Mao's kroonprins, defensieminister Lin Biao, een greep naar de macht. Dit 'Project 571' mislukte en op de vlucht naar Moskou werd boven Mongolië Lins vliegtuig neergehaald. Na Mao's dood grepen Ye en het leger weer in, namen zijn weduwe Jiang Qing en haar aanhang gevangen en zorgden dat Deng Xiaoping de nieuwe leider werd. Er was weer eenheid in commando over staat en krijgsmacht. Precies die incoherentie is het grote risico dat Xi nu loopt. De onzekerheid over de politieke ontwikkelingen en stabiliteit van China verhoogt de toch al labiele situatie wereldwijd. Dat bijvoorbeeld zeer recent India en de EU, maar ook de EU en Vietnam nadrukkelijk elkaar als strategische partners hebben gevonden heeft hier alles mee te maken. Dat Nederland als het land van ASML in deze troebelen rond Taiwan, China, Japan en Amerika een belangrijke rol speelt, had Den Haag zich kortgeleden nog niet kunnen indenken. De agenda van Rob Jetten en het strategisch inzicht van zijn ministers Tom Berendsen en Sjoerd Sjoerdsma worden al bij aantreden danig op de proef gesteld. *** Verder kijken Volksbevrijdingsleger - Lange Mars Musical (1976) *** Verder luisteren Xi Jinping 453 – 75 jaar Volksrepubliek China, waar is het feestje? 306 - De gevoelige geopolitieke relatie met China24 - Ties Dams over China's nieuwe keizer Xi Jinping China en zijn leiders250 - Nixon in China: de week die de wereld veranderde 225 - Nixon in China: Henry Kissinger's geheime (en hilarische) trip naar Beijing 245 - Oompje neemt de trein – de reis die China naar de 21e eeuw bracht 220 - China's nieuwe culturele revolutie 58 - 70 jaar China, de Volksrepubliek van Mao, Deng en Xi Geopolitieke troebelen 549 - China en Japan op ramkoers 458 - De gedroomde nieuwe wereldorde van Poetin en Xi Lessen voor Jetten, Berendsen en Sjoerdsma 551 – Klem tussen Amerika en China: de koude oorlog rond ASML 558 – Poetins rampjaar, Jettens kans *** Tijdlijn 00:00:00 – Deel 1 00:22:55 – Deel 2 00:45:49 – Deel 3 01:27:10 – EindeSee omnystudio.com/listener for privacy information.
How do you build an organization that can absorb change, learn from failure, and keep patients at the center—even when the science is uncertain? Nelly Viseux shares lessons from over 20 years in biotech and a decade leading cell and gene therapy development.Nelly discusses how she structured a 100-person CMC organization at Regeneron to balance innovation with operational execution, why documenting your assumptions is critical to managing risk, and what it really takes to maintain resilience when you're literally holding patient lives in your hands.A few of Nelly's key takeaways:Resilience is adaptability—build organizations that absorb and anticipate change rather than resist itSeparate innovation from execution with intentional gates for when new approaches are ready to implementDocument your assumptions so you can revisit decisions effectively when circumstances changeFailure is a process problem, not a personal one—root cause analysis should improve systems, not assign blameData is the common language that aligns scientists, regulators, and stakeholdersEveryone is a leader in cell therapy—manufacturing and QC teams hold patient lives in their handsAbout Nelly ViseuxNelly Viseux is Vice President of Cell Therapies Development, Manufacturing, Supply & Quality at Regeneron, leading a 100-person organization supporting autologous cell therapy programs. She has over 20 years of biotechnology experience spanning large pharma (Shire, Biogen, Baxter) and startups, working across cell and gene therapies, biologics, and nanoparticles. Her accomplishments include building a Phase 1 cell therapy manufacturing facility that achieved 100% cGMP success and first IND submission within two years. She holds a Ph.D. in Biochemistry and Molecular Biology from University of Lille and is a member of the Society for Immunotherapy of Cancer and the American Society of Gene & Cell Therapy.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle—from clinical development to commercialization—with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/
Xi, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission (CMC), conveyed the greetings while attending a gala held by the CMC for retired military officers of Beijing-based troops on Friday.Greeted with warm applause, Xi chatted with the veterans, inquiring about their health and living conditions. Together, they reviewed the extraordinary journey of the Party, the country and the military over the past year.The veterans vowed to rally more closely around the CPC Central Committee with Comrade Xi Jinping at its core and act on Xi Jinping Thought on Strengthening the Military.They pledged to gain a deep understanding of the decisive significance of establishing Comrade Xi Jinping's core position on the Party Central Committee and in the Party as a whole and of establishing the guiding role of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era. They also vowed to consciously uphold Comrade Xi Jinping's core position on the Party Central Committee and in the Party as a whole and uphold the Central Committee's authority and its centralized, unified leadership.Moreover, the veterans pledged to implement the system of ultimate responsibility resting with the CMC chairman.The veterans vowed to contribute their part to achieving the centenary goals of the People's Liberation Army by 2027 and to advancing the modernization of national defense and the armed forces at a high standard.People's Liberation Army (PLA) /ˈpiːpəlz ˌlɪbəˈreɪʃn ˈɑːmi/中国人民解放军retired military officers /rɪˈtaɪərd ˈmɪlɪtəri ˈɒfɪsəz/军队离退休干部rally around /ˈræli əˈraʊnd/团结在……周围
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Superbowl LX is here, Shams is shameful, Tom Brady is getting torched on social media like the good ol days, Cooper Flagg is doing amazing things, Matt Stafford is the MVP, Giannis isn't f***ing leaving. All this and more is discussed on the 140th edition to A Different Sports Show. If you love this, catch us at ADifferentConversation.net. You won't find a place with better laughs, hotter takes, and everything different! 00:00:00- Pre-Show 00:01:18- Introduction, Shams terrible NBA deadline reporting 00:07:56- Cooper Flagg on a tear 00:10:13- Tom Brady Superbowl backlash 00:13:53- Matthew Stafford MVP + Award show conversation (Maye, Vrabel, CMC, Dak Prescott) 00:22:27- Superbowl LX predictions and conversation 00:32:47- NBA Trade Deadline fall out to conclusion #Patriots #Seahawks #NBA #NFL #Superbowl #Rams #Cowboys #Dak #Wizards #Cavaliers
Dirty Work Hour 3: The Boys bring you another flaming edition of the Sound Soiree featuring: CMC, Tiffany Haddish, & an enraged Knicks fan, & they also sit down with legendary sportscaster Kenny Mayne to talk Super Bowl.See omnystudio.com/listener for privacy information.
Send us a textSteven & Derek discuss the latest on Maxx Crosby's future with the Raiders, react to the NFL Honors, Pro Football Hall of Fame Class of 2026 & preview Super Bowl 60 between the Seahawks & Patriots (00:58)-Lindsey Vonn skiing with a torn ACL (07:23)-Media row in San Francisco (19:45)-Reaction to Jay Glazer saying Maxx Crosby is done with the Raiders & Crosby's comments (48:27)-49ers playing the Rams in Australia next season (54:34)-NFL Honor Awards: Stafford wins MVP by a vote, CMC gets Comeback Player of the year & more (01:14:49)-Hall of Fame Class: Roger Craig finally gets in, along with Drew Brees, Larry Fitzgerald, Adam Vinateri & Luke Kuechly (01:23:55)-Super Bowl 60 Preview (01:35:12)-Jackass of the Week (01:47:01)-Pop Culture Catch-Up (01:52:34)-Moments of Zen: Gruden sees Gannon in the streets of SF Support the show
Dirty Work Hour 3: The Boys bring you another flaming edition of the Sound Soiree featuring: CMC, Tiffany Haddish, & an enraged Knicks fan, & they also sit down with legendary sportscaster Kenny Mayne to talk Super Bowl.See omnystudio.com/listener for privacy information.
Damon Bruce Plus: Warriors, 49ers, Giants, A’s Bay Area Sports Talk
2:55: No one on Media Row actually seems to be talking about the Super Bowl 10:12: The death of journalism is the plan: 16:11: Jeffery Simmons joins the show: 34:01: Ike joins the show: 37:41: Ed McCaffrey 58:53: Today in history: Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Dirty Work Hour 1: Legendary broadcaster, Kevin Harlan joins the boys to break down the Super Bowl, the Warriors huge win over the Suns, & the crew also break down NFL Awards Night & 49ers running backs getting snubbed & honored (Roger Craig, CMC, Frank Gore)See omnystudio.com/listener for privacy information.
Hour 1: Papa & Silver discuss Roger Craig making the Hall of Fame, and touch on CMC winning the comeback player of the year award. Chris Berman joins the show to share his favorite Super Bowl moments. Matt Maiocco joins the show to discuss why Roger Craig deserves to be in the Hall of Fame and why he finally got the nod. See omnystudio.com/listener for privacy information.
Dirty Work Hour 1: Legendary broadcaster, Kevin Harlan joins the boys to break down the Super Bowl, the Warriors huge win over the Suns, & the crew also break down NFL Awards Night & 49ers running backs getting snubbed & honored (Roger Craig, CMC, Frank Gore)See omnystudio.com/listener for privacy information.
Hour 1: Papa & Silver discuss Roger Craig making the Hall of Fame, and touch on CMC winning the comeback player of the year award. Chris Berman joins the show to share his favorite Super Bowl moments. Matt Maiocco joins the show to discuss why Roger Craig deserves to be in the Hall of Fame and why he finally got the nod. See omnystudio.com/listener for privacy information.
Star running back Christian McCaffrey joined "49ers Talk" host Matt Maiocco on Day 3 of Super Bowl Radio Row at Moscone Center to share his pride in receiving the NFL's 15th annual Salute to Service Award and offer his support to Hall of Fame candidate Roger Craig. Next up was another 49ers legend, Terrell Owens, who stopped by to relive his iconic Sharpie celebration and offer his critique on the Hall of Fame selection process. San Francisco rookie CJ West popped in to discuss areas he can improve in his sophomore season, and former wily quarterback for the Red and Gold, Jeff Garica, shared how he believes current starter Brock Purdy's "underdog" mentality keeps him competitive. Finally, former defensive back Logan Ryan details what traits Upton Stout possesses to be the 49ers' next great nickel corner.--(7:00) CMC honored to receive Salute to Service Award, supports Roger Craig's HOF bid(18:00) Terrell Owens reminisces on iconic Sharpie celebration, discusses Kraft, Belichick HOF snubs(33:00) Where 49ers DT CJ West hopes to improve in his sophomore 49ers season(40:00) Jeff Garcia shares how Brock Purdy's ‘underdog' mentality keeps him competitive(50:00) Former 49ers DB Logan Ryan believes the 49ers found their next great nickel corner in Upton Stout Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, BA, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 years on Feedspot.Sonal's 17th Season starts up and Episode 1 features a Newsworthy update on 5 new telehealth services in 2026.Sonal's Trusty Tip and compliance recommendations focus on audit plans for office visits rendered via telehealth.Spark inspires us all to reflect on beauty, abundance, and innovation based on the inspirational words of Kahlil Gibran.Check out Sonal's NAMAS article:https://namas.co/5-steps-to-update-your-audit-plan-for-office-visits-via-telehealth/Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology.Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact.In this episode, you'll learn:The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)Strategies for building more predictive, clinically relevant research models (06:09)Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)Strategic insight:Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited.Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond?Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies.Connect with Bryan Miller:LinkedIn: www.linkedin.com/in/bryan-miller-148344aaCrown Bioscience: www.crownbio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Randy Abbey is not at peace with the MD of CMC because President Mahama revoked an appointment Randy made - Charles McCarthy (MD, the Hawk Newspaper)
Fine, light, textured, yet strong. Donations, Merchandise, Newsletter, more: https://www.podrunner.com Groovelectric: Downloadable Soul https://www.groovelectric.com PLAYLIST 01. Diana May - Distant (Tim Kollberg Remix) 02. Roald Velden - Letting Go 03. Roald Velden - In My Dreams You're Always There 04. Martina Budde X Da Clubbmaster - Everybody Wants to Rule (Extended Mix) 05. Nipika & Haris V. - Staying Strong (Instrumental Mix) 06. Shyro & Anix Jay - Divine Waves (Devin Jay Remix) 07. Rockka & Kryptone (SL) - Resurgent (Morning Mix) 08. Coss Bocanegra - Somos Como Una Flor 09. Gad Ben David - Olympus 10. Deep Sure, Denis Vostru - Hummingbird 11. CMC & Silenta - Gonna Be Alright (Intrumental) 12. Cosmin Fogoros & Alex Modoi - Chasing Cars (Extended Mix) == Please support these artists == Podrunner is a registered trademark of Podrunner LLC. Music copyright © or CC the respective artists. All other material ©2006, 2026 by Podrunner LLC. For personal use only. Any unauthorized reproduction, editing, exhibition, sale, rental, exchange, public performance, or broadcast of this audio is prohibited. No part of Podrunner or its website and associated content may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems.
Covino & Rich broadcast live from Radio Row in San Francisco for Super Bowl 60 in this Best Of edition! The guys are joined by the Panthers QB Bryce Young & Running Back Rico Dowdle to talk all things about locker room dynamics & how the team will be back better than ever next year. 49ers Wide Receiver Kendrick Bourne joins the guys to talk about their one of a kind of comradery in the locker room, how CMC has been such a huge part of that strong team foundation + Comedian Frank Caliendo stops by! See omnystudio.com/listener for privacy information.
49ers Wide Receiver Kendrick Bourne joins the guys to talk about the team's one of a kind of comradery in the locker room, how CMC has been such a huge part of that strong team foundation & if he believes there’s some kind of truth behind those practice field conspiracies in San Fran! Comedian Frank Caliendo swings by & goes over the impressions the guys always do on a regular basis! See omnystudio.com/listener for privacy information.
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Resultado operacional de 25% não é sorte, é engenharia de gestão.No nosso mercado, muitos tratam o sucesso como algo subjetivo, mas a verdade é que o poder de realização do gestor de um negócio está diretamente ligado à qualidade da sua gestão de números. Quando você domina seus dados (DRE,CMV, CMC, CMO …) o que parecia impossível se torna uma meta palpável.Ter a gestão dos números bem feita permite:Enxergar o invisível: Descobrir onde a eficiência está sendo drenada;Subir o sarrafo: Entender que se um resultado de 22% ou 25% é possível, a sua gestão tem o dever de buscá-lo;Segurança para realizar: Números dão o suporte necessário para você tomar decisões ousadas e escalar com pé no chão.Não se contente com o que é comum. A gestão intencional transforma a inspiração em execução e o potencial em lucro real. Se os números mostram que o caminho existe, o seu poder de realização é o que vai te levar até lá.A gestão dos dados é o que separa quem sonha com o sucesso de quem realiza o resultado, e pra ilustrar tudo isso a gente conversou com a Fernanda Lee, sócia do Ariga Food, Dacho Sushi e do recém inaugurado Tõ Asian Food.
Following Robert Saleh's hiring as Tennessee Titans head coach, sources confirmed to NBC Sports Bay Area that Raheem Morris will sign on as San Francisco's fifth defensive coordinator in the last five seasons. Also, in another top organizational move, Jed York announced Monday the promotion of Al Guido to the role of CEO. On this episode of "49ers Talk," Matt Maiocco sits down with Guido to discuss his promotion, his hard work in bringing Super Bowl LX to the Bay Area and how the 49ers' front office and coaching staff's synergy has provided stability that is rare in the NFL these days. They also touch upon the logistics required to host a Super Bowl twice in 10 years, and the possibility of the 49ers playing two international games this coming season. Matt also interviews talkSPORT commentator Will Gavin about his viral call of the "Skyy Bang Reverse Pass" play that was key to San Francisco's fourth-quarter comeback vs. the Eagles in NFC wild-card playoffs.--6:00 - 1-on-1 with newly promoted 49ers CEO Al Guido12:00 Guido's work on bringing Super Bowl LX to Levi's14:00 - Dynamic between the coaching staff and 49ers' front office19:00 - 49ers are in a window next season to play international home game or two20:00 - talkSPORT commentator Will Gavin breaks down viral call of 49ers play23:00 - More people have contacted CMC about the call than the actual play Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Imagine treating cancer with the precision of a guided missile—delivering radioactive payloads directly to tumor cells. Radiopharmaceuticals are reshaping cancer diagnostics and therapy by pairing tumor-targeting molecules with radioisotopes for diagnosis or therapy. But what does it really take to develop these therapies, and why is interest from scientists, biotech companies, and pharma accelerating?In this episode, we're joined by Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK. From a PhD in cardiac disease to leading preclinical oncology and radiopharmaceutical programs, Bryan brings hands-on insight into building advanced cancer models and translating innovative therapies from bench to clinic.Topics discussed include:Bryan Miller's path from cardiac disease research to leading preclinical cancer model development (03:03)Crown Bioscience's comprehensive cancer model platforms, from organoids to PDX and humanized in vivo models (04:05)How radiopharmaceuticals differ from traditional chemotherapies in terms of safety and speed, including the concept of theranostics (07:32)The reasons behind the surge of interest in radiopharmaceuticals within science and industry (09:04)The importance of selecting the right preclinical model for success—and how AI and data-driven approaches will shape future workflows (10:11)Critical pitfalls and unique technical challenges in radiopharmaceutical drug development (12:46)Crown Bioscience's collaborative approach with Medicines Discovery Catapult to navigate the complexities of radiopharmaceutical research (13:35)The diverse client needs, from small startups to global pharma companies, and how mature their development programs can be (14:20)Strategies for scaling preclinical and translational capabilities to meet growing demand in radiopharmaceutical studies (16:04)Strategic insight:Radiopharmaceutical success requires integrated design from the start—combining precise model selection, targeting strategy, isotope choice, linker chemistry, and rigorous QC. Programs that establish this comprehensive foundation early move faster and with higher translational confidence than those addressing these elements sequentially or treating any aspect as a downstream refinement.If you're curious about the real challenges of drug development, the rise of theranostics, and how data-driven approaches (including AI) are shaping preclinical workflows, this episode delivers actionable strategies and insider perspectives for scientists and biotech innovators alike.Connect with Bryan Miller:LinkedIn: www.linkedin.com/in/bryan-miller-148344aaCrown Bioscience: www.crownbio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
The cultivated meat industry has captured headlines and struggled with economics. Meanwhile, plant cell biomanufacturing is quietly solving the cost equation and approaching commercial launch. The question isn't whether cellular agriculture can work at scale. It's which applications will get there first, and what bioprocessing innovations will make it possible.In Part 2, we dive into the commercialization challenges that separate laboratory curiosity from market-ready products. Steven Lang tackles the hard questions: How do you replicate chocolate's complex flavor profile without traditional fermentation? What analytical infrastructure ensures product consistency and safety? And how do you build the right team and data foundation to navigate the journey from premium launch to commodity-scale production?Steven's background spanning Johnson & Johnson, Genentech, and Upside Foods gives him a unique perspective on what works and what doesn't when translating biopharma rigor to food applications. At California Cultured, he's applying those lessons to launch high-flavanol cocoa powder in 2026, with a clear roadmap to commodity cocoa and coffee thereafter.In this episode:The challenge of replicating chocolate's taste and fermentation in the lab (02:39)How plant cell culture differs from conventional farming and its advantages for safety and scalability (03:03)Analytical methods and equipment needed for consistent, safe, and high-quality cultured cocoa products (05:05)The potential for cell-based food to minimize heavy metals and other contaminants in chocolate (06:09)Environmental implications: tackling climate change, deforestation, and the realistic timeline for widespread adoption of lab-grown foods (06:50)Emerging opportunities beyond cocoa and coffee—saffron, ginseng, echinacea, and even lab-grown wood (08:40)Key advice for scientists and entrepreneurs interested in entering the cellular agriculture field (10:12)Building successful teams and robust data foundations in biotech startups (11:43)Key takeaway:Cellular agriculture's future isn't a single technology replacing conventional food production. It's multiple parallel approaches creating resilience in global food systems. The opportunity is clear: the technical principles you've mastered in biopharma translate directly to food applications, but the faster commercialization timelines and novel business models require rethinking what "stage-appropriate development" means.The question for bioprocess leaders is whether you'll help build the solutions to bridge the food production gap, or watch from the sidelines as food security becomes the defining challenge of our generation.Here is the previous conversation with Steven Lang:Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven LangConnect with Steven Lang:LinkedIn: www.linkedin.com/in/steven-lang-b003406California Cultured Inc.: www.cacultured.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
On today's show Andrew and Bill react to the news that the rumors were true, and CMC members Zhang Youxia and Liu Zhenli are under investigation for corruption. Topics include: The timing of the announcement from the Defense Ministry, why this weekend's news inspired such a volume of reactions around the world, a history of Xi's crackdowns on the PLA, questions about rumors of a coup against Xi, reports that Zhang Youxia was working with the U.S., the PLA corruption heyday and its implications for what might come next, and various ways to think about the implications for Taiwan. At the end: The first batch of H-200s is approved for purchase, and the TikTok sale is approved as users lash out with censorship claims.
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
In this episode of Inside Winemaking, Jim Duane speaks with Leigh Meyering of MyEnologist about the practical and analytical aspects of heat and cold stability in wine. The discussion focuses on how and why protein haze and tartrate instability occur, with an emphasis on white and rosé wines. Leigh explains the principles behind heat stability testing, protein denaturation, and the use of bentonite to prevent haze, as well as how stability concerns differ between red wines and lighter-colored styles. The conversation also addresses the sensory and chemical impacts of stabilization decisions, including common concerns around stripping, mouthfeel, and visual clarity in finished wines. The episode then moves into cold stability, detailing the Davis conductivity, DIT, and ISTC 50 tests and how to choose the appropriate method based on a winery's stabilization strategy. Leigh outlines the roles of traditional chilling and seeding, carboxymethyl cellulose (CMC), and mannoproteins, including their limitations and compatibility with protein stability. Throughout the discussion, Jim and Leigh emphasize correct sampling strategy, filtration level selection, and timing of tests to ensure results accurately represent the wine that will be bottled. Practical lab workflows, sample volume requirements, and real-world bottling considerations are covered to help winemakers reduce risk and avoid post-bottling stability issues. Leigh previously appeared on Inside Winemaking in May 2019 to discuss the founding and early development of her wine lab, MyEnologist, including its analytical services and role in supporting winemakers. This episode builds on that earlier conversation by applying lab-based analysis directly to cellar decision-making, with a focused, technical look at stability testing and intervention strategies used in modern winemaking.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he's now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
2026-01-26 | UPDATES #113 | “Treason” in the PLA? Xi's unprecedented purge — corruption, loyalty, and coup rumours. Today's story is not “just another corruption scandal” in China. This is the Chinese Communist Party reaching up into the absolute top of the People's Liberation Army — right into the room where war plans live — and yanking out two senior figures in one move. Top figures in fact. Beijing's official language is clipped. The implications are not. China's defence ministry says it has opened investigations into General Zhang Youxia — a vice chairman of the Central Military Commission, effectively the uniformed number two under Xi Jinping — and General Liu Zhenli, a CMC member and chief of the Joint Staff Department. The stated reason: “suspected serious violations of discipline and law.” (Reuters)----------SUPPORT THE CHANNEL:https://www.buymeacoffee.com/siliconcurtainhttps://www.patreon.com/siliconcurtain----------SOURCES: Xinhua: Defence ministry announcement (Jan 24, 2026). Xinhua / PLA Daily editorial summary (Jan 24, 2026). Reuters: Investigation details and context on PLA purges (Jan 24, 2026). Associated Press: Overview and recent purge timeline (Jan 24, 2026).Financial Times: Loyalty framing and “authority” angle (Jan 25, 2026). Washington Post: Scale of upheaval and command implications (Jan 25, 2026).Wall Street Journal: Reported additional allegations (unconfirmed by PRC statement) South China Morning Post: “Party purity” framing and political timing (Jan 25, 2026). Official explainer of the “CMC Chairperson Responsibility System” (SCIO, background).Reuters (background): Li Shangfu/Wei Fenghe expulsions (Jun 2024) and 2027 readiness reporting (Feb 2023). German Marshall Fund (background): Rocket Force shakeup (Aug 2023). Andrew Erickson (analysis aggregation; includes translated/linked primary text). Sinocism (analysis; discussion of messaging speed and implications). ----------SILICON CURTAIN LIVE EVENTS - FUNDRAISER CAMPAIGN Events in 2025 - Advocacy for a Ukrainian victory with Silicon Curtainhttps://buymeacoffee.com/siliconcurtain/extrasOur events of the first half of the year in Lviv, Kyiv and Odesa were a huge success. Now we need to maintain this momentum, and change the tide towards a Ukrainian victory. The Silicon Curtain Roadshow is an ambitious campaign to run a minimum of 12 events in 2025, and potentially many more. Any support you can provide for the fundraising campaign would be gratefully appreciated. https://buymeacoffee.com/siliconcurtain/extras----------
What happens when we move beyond oversimplified cell cultures and truly embrace the complexity of human biology? In this episode of the Smart Biotech Scientist Podcast, we explore how advanced 3D cell models are reshaping preclinical research—recreating human tissue microenvironments to better understand tumors, immunotherapies, and gene and cell therapies.David's guest is Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA (Portugal). Her work bridges academia and industry through iBET, a unique partnering organization that integrates cell engineering, bioprocessing, and translational modeling.Catarina's pioneering models help both pharma leaders and startups predict drug resistance and immunogenicity earlier and more reliably, accelerating the path to safer, more effective therapies—well before clinical trials begin.Topics discussed:Understanding the contribution of stromal and immune cells to therapy outcomes in tumor microenvironments (03:42)Studying immune responses to gene therapy vectors with advanced neural models (04:31)Combining multi-omics and spatial data with AI for predictive biology and patient-specific digital twins (05:16)Catarina's advice: Start simple, let the biological question dictate model design, and avoid premature overengineering (06:53)Importance of reproducibility, process controls, and standardization in advanced models (08:10)How academic-industry collaborations drive model development, scalability, and real-world relevance (08:42)Common pitfalls: Overengineering, poor cell source selection, insufficient system validation (11:03)Next steps for precision medicine and translational research using advanced cell models (13:08)Want to know how leading scientists make advanced cell models actionable and collaborative for pharma breakthroughs? Tune in for practical strategies, real-world collaborations, and pitfalls to avoid as you scale your own translational research.Connect with Catarina Brito:LinkedIn: www.linkedin.com/in/catarina-brito-ibetAdvanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-labNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
What if the failure rate in clinical trials isn't about picking the wrong drug candidates—but about testing them in the wrong models?When you move cells from a 2D culture plate into a bioreactor, you're not simply scaling volume. You're fundamentally changing the biological context. Cell density shifts. Mass transfer dynamics evolve. Mechanical cues emerge. The cells sense these changes and respond—often in ways that derail strategies built on oversimplified assumptions.Most preclinical research still relies on flat plastic surfaces and animal models that miss critical aspects of human biology. The result? Therapeutics fail late in development because the models couldn't predict how human tissues would actually respond.In this episode, David Brühlmann speaks with Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA in Portugal. Catarina's career-defining insight came early: studying glycan-protein interactions in murine versus human cells revealed that species differences weren't just nuances—they were fundamental gaps that could mislead entire research programs.Catarina and her team have developed neural, liver, and tumor models that capture the multicellular complexity and microenvironmental cues that 2D cultures cannot replicate. Her work creates preclinical models sophisticated enough to predict human responses while remaining scalable for drug development workflows.Highlights of the episode:Limitations of traditional 2D cell cultures and animal models in capturing realistic tissue behavior and therapeutic responses (06:27)Catarina Brito's personal scientific journey: from discovering model limitations to pioneering 3D culture systems in neural and liver tissues (04:19)How advanced 3D models recreate cell-to-cell interactions, tissue-specific microenvironments, diffusion gradients, and multicellular complexity (10:35)Regulatory movements toward reducing animal models, and the challenge of validating advanced alternatives for systemic biology studies (09:10)Key differences in designing bioreactors for various cell types, with practical examples from liver and neural models (15:16)The impact of scalable, robust 3D models on accelerating drug development and improving selection of candidate therapies (17:22)Key Takeaway:Bioprocess development starts when you choose the model that validates your therapeutic approach. If that model can't capture the biology that matters, every downstream optimization is built on a flawed foundation.In Part 2, Catarina reveals how 3D tumor microenvironments expose drug resistance mechanisms invisible in 2D cultures, and her vision for AI-powered digital twins enabling personalized medicine.Subscribe & Review:If this conversation changed how you think about preclinical model selection, leave a review on Apple Podcasts. Your reviews help other biotech scientists discover these insights.For more CMC development insights, visit smartbiotechscientist.com.Connect with Catarina Brito:LinkedIn: www.linkedin.com/in/catarina-brito-ibetAdvanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-labNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Seahawks, Broncos WIN.. Nix ankle; CMC injury
The biotech industry stands on the verge of a radical transformation thanks to artificial intelligence (AI) and machine learning (ML). But even the most sophisticated algorithms are only as smart as the data feeding them.David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, whose team has quietly shattered the data ceiling by measuring and curating more than 1.8 billion protein interactions. Troy Lionberger brings an insider's perspective from the frontlines of machine learning-powered drug discovery. From partnering with leading biotechs to redesigning classic antibodies for previously “impossible” targets, Troy's work pushes the edges of what's tractable in biologic therapeutics.What you'll hear in this episode:Limitations of public data sources like the Protein Data Bank and their impact on current protein engineering approaches (03:11)Why combining energetic (ΔG) and structural data matters for building predictive protein engineering models (05:43)A-Alpha Bio's approach to generating 1.8 billion protein interaction measurements for machine learning—what this enables today and what's possible next (06:30)Examples of how A-Alpha Bio's platform solves challenging therapeutic problems, such as optimizing molecules for 800+ HIV variants and engineering dual-specific antibodies (07:36)The ongoing debate: What capabilities should biotech companies keep in-house, and what works best outsourced to service providers? (09:59)The potential of synthetic epitopes as vital tools for training models beyond the Protein Data Bank—introducing the Synthetic Epitope Atlas (12:09)Key takeaways for scientists: the importance of diligence amidst rapidly evolving AI claims, and advice for accelerating R&D with the right data (14:57)Wondering how to move protein therapeutics from “interesting” to “impactful” without waiting for years of crystal structures? Listen in to learn how you can harness next-gen machine learning tools and custom datasets for your development projects.Connect with Troy Lionberger:LinkedIn: www.linkedin.com/in/troylionbergerA-Alpha Bio website: www.aalphabio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Spadoni and Shasky discuss the Warriors win, Fred Warner's return and the guys play with some hypotheticals to show how desperate 49ers fans are to win the Super Bowl. Plus, who are guys that were traded that felt like they lived their career in one spot, like CMC?
In this edition of What the Bleep, Celtics head coach Joe Mazzulla goes viral for another excellent press conference, a young Eagles fan talks about a tough playoff loss, Jason Garrett had an unfortunate misspeak on CMC, a woman has a food snorting addiction, & more See omnystudio.com/listener for privacy information.
Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.In this episode, you'll learn about:The historical and current challenges in characterizing these interactions at scale (06:22)How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)Real-world examples of how A-Alpha Bio's approach is compressing years of work into months without sacrificing quality (13:58)The science behind A-Alpha Bio's AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)The practical affinity range the technology can measure, covering most therapeutic applications (23:25)Whether you're a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.Connect with Troy Lionberger:LinkedIn: www.linkedin.com/in/troylionbergerA-Alpha Bio website: www.aalphabio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show
Hour 1: From underdogs to upset kings! The Niners storm Philly with a 23–19 win behind Brock Purdy’s clutch late TD and a jaw‑dropping trick‑play pass from Jauan Jennings to CMC, and KNBR 49ers insider Larry Krueger joins the show to break it all downSee omnystudio.com/listener for privacy information.
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Every Wednesday in January, Matt Harmon and Justin Boone take a look back at the 2025 fantasy season to find lessons they learned and can apply to the 2026 fantasy season. For today's pod the two look at their biggest takes from last summer to see what they got right and wrong at the QB and RB position. To end the show, Harmon debuts our new 'Dynasty Debates' segment where listeners send in their most pressing dynasty questions this fantasy offseason.(4:50) -Things we got WRONG at QB: Matthew Stafford, Bryce Young, JJ McCarthy(21:45) - Things we got WRONG at RB: Cowboys Backfield, Seahawks Backfield, Saquon Barkley(33:45) - Things we got RIGHT at QB: Drake Maye, Trevor Lawrence, Dak Prescott, Kyler Murray(41:50) - Things we got RIGHT at RB: Ashton Jeanty, CMC, TreVeyon Henderson, Chase Brown, RJ Harvey, Bijan Robinson(51:15) - Dynasty Debates: Matt and Justin answer your questions Subscribe to the Yahoo Fantasy Forecast on your favorite podcast app:
© 2020-2026 Ivy Podcast Discovery LLC
